论文部分内容阅读
目的探究异甘草酸镁联合门冬氨酸鸟氨酸治疗乙肝肝硬化肝性脑病的临床疗效。方法 30例乙肝肝硬化肝性脑病患者,随机分为实验组和常规组,每组15例。常规组患者实施门冬氨酸鸟氨酸,实验组患者实施异甘草酸镁联合门冬氨酸鸟氨酸,治疗后对两组患者的治疗效果进行评定。结果两组患者接受治疗后,实验组中10例显效,4例有效,1例无效,治疗总有效率为93.33%;常规组患者中7例显效,2例有效,6例无效,治疗总有效率为60.00%。两组患者临床治疗效果比较差异具有统计学意义(P<0.05);治疗后,实验组患者的丙氨酸转氨酶(ALT)、血胆红素以及血氨分别是(48.79±12.56)U/L、(51.02±7.89)mmol/L、(42.30±11.02)μmol/L,常规组患者的ALT、血胆红素以及血氨分别是(85.02±18.56)U/L、(72.25±9.87)mmol/L、(59.56±14.98)μmol/L,两组比较差异具有统计学意义(P<0.05)。实验组患者的肝功能改善状况明显优于常规组(P<0.05)。结论异甘草酸镁联合门冬氨酸鸟氨酸治疗乙肝肝硬化肝性脑病患者的效果非常好,值得在临床上进行推广。
Objective To investigate the clinical efficacy of magnesium isoglycyrrhizinate combined with aspartate ornithine in the treatment of hepatic cirrhosis with hepatitis B cirrhosis. Methods Thirty patients with hepatitis B cirrhosis with hepatic encephalopathy were randomly divided into experimental group and conventional group, with 15 cases in each group. Aspartate ornithine was administered to patients in the conventional group and magnesium oryzine combined with aspartate ornithine in the experimental group. The therapeutic effects of the two groups were evaluated after treatment. Results After treatment, 10 cases in the experimental group were markedly effective, 4 cases were effective, 1 case was ineffective, and the total effective rate was 93.33%. In the conventional group, 7 cases were effective, 2 cases were effective and 6 cases were ineffective. Efficiency is 60.00%. After treatment, the levels of ALT, Bilirubin and ammonia in the experimental group were (48.79 ± 12.56) U / L , (51.02 ± 7.89) mmol / L and (42.30 ± 11.02) μmol / L, respectively. The levels of ALT, serum bilirubin and ammonia in the routine group were (85.02 ± 18.56) U / L and (72.25 ± 9.87) mmol / L, (59.56 ± 14.98) μmol / L, the difference between the two groups was statistically significant (P <0.05). The improvement of liver function in the experimental group was significantly better than that in the conventional group (P <0.05). CONCLUSION Magnesium isoglycyrrhizinate combined with aspartate ornithine has a very good effect in the treatment of hepatic encephalopathy in patients with hepatitis B cirrhosis and is worthy of clinical promotion.